The Oncology Brothers—Rahul Gosain, MD, of the University of Rochester, and Rohit Gosain, MD, of the UPMC Hillman Cancer Center—were live at ASCO 2023 to discuss findings from the TROPiCS-02 study with Aditya Bardia, MD, of Massachusetts General Hospital at Harvard Medical School. Dr. Bardia discussed the Trop-2-directed antibody-drug conjugate sacituzumab govitecan, which is FDA-approved for patients with metastatic triple-negative breast cancer in the first-line and later setting, as well as patients with metastatic hormone receptor-positive (HR+) breast cancer who have received at least 2 prior lines of systemic therapy. ...
Advertisement
ASCO 2023: The Oncology Brothers Discuss ADAURA Trial Findings of Osimertinib for EGFR-Mutated NSCLC
The Oncology Brothers discuss findings from the phase 3 ADAURA trial.
Dr. Patrick Forde spoke with DocWire News at ASCO 2023 about updated data from the CheckMate 816 trial.
The American College of Rheumatology has released new recommendations for the management of rheumatoid arthritis.
The following question refers to Section 7.1 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
DocWire Content Partners
Get insights for cardiologists from the CardioNerds.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan discusses medical advances with renowned experts.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Expert interviews with Dr. Payal Kohli
